MAP2K7 and breast carcinoma: From a clinical perspective, the addition of a toxic inhibitor therapeutic to standard-of-care chemotherapies offered to patients with IDC breast cancer is infeasible, as chemotherapeutics employed for IDC, specifically the TNBC subset, cause significant side effects without the added burden of an MEK inhibitor [43].